The BioShares Biotechnology Products Fund (BBP) has capitalized on a string of acquisitions and outperformed other biotechnology- and pharmaceuticals-related exchange traded funds. BBP, which follows ...

The Biotechnology sector is known to carry inherent risks as the stock price of a company in this sector can vary wildly based on the outcomes of clinical trials of drugs and regulatory interventions.

Barghest Building Performance (BBP) announced yesterday that it has received up to SGD45 million (US$32.8 million) investment from global investment firm KKR. BBP is a Singapore-based provider of ...

Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for rare tumor treatments and immediate revenue growth. Lekha Gupta FDA Set To ...

The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. The Index seeks to track the performance of ...